A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer.
Conclusions: Despite lessened aes and preserved qol, atezolizumab is not considered cost-effective for the second-line treatment of mbc.
PMID: 32905260 [PubMed - as supplied by publisher]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Bladder Cancer | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Health Management